Azenam 250 Injection

Aztreonam
250mg
Aristo Pharmaceuticals Ltd.
Pack size 1
Dispensing mode
Source
Agent
Retail Price

Indications

Azenam 250 Injection is used for: Bone and joint infections; Intra-abdominal infections; Lower respiratory tract infections; Meningitis; Septicaemia; Skin and soft tissue infections ; Pelvic infections, Gonorrhoea; Cystitis, Urinary tract infections, Cystic fibrosis

Adult Dose

Adult: IV/IM Gm-ve infections 1-8 g/day in divided doses depending on severity. Max: 8 g/day. UTI 0.5-1 g 8-12 hrly. IM Cystitis; Gonorrhoea 1 g as a single dose.

Child Dose

Child: IV, IM 90–120 mg/kg/day q6–8hr Infants >1 wk: 30 mg/kg every 6 or 8 hr

Renal Dose

Renal impairment CrCl 10-30 mL/min: 1-2 g loading dose, then 50% of usual dosage CrCl <10 mL/min: 1-2 g loading dose, then 25% of usual dosage

Administration

Reconstitution: IM: Reconstitute vial w/ at least 3 mL of sterile water for inj, sterile bacteriostatic water for inj, normal saline, or bacteriostatic NaCl per g of aztreonam; immediately shake vigorously. IV: Bolus inj: Reconstitute vial w/ 6-10 mL of sterile water for inj. Infusion: Reconstitute vial w/ at least 3 mL of sterile water for inj per g of aztreonam; immediately shake vigorously. Then further dilute in an appropriate soln for infusion to a final concentration of <2%.

Contra Indications

Hypersensitivity to aztreonam.

Precautions

History of β-lactam hypersensitivity. Renal and hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor for signs of anaphylaxis during 1st dose; periodic LFT. Consider measuring FEV1 prior to initiation of inhalation therapy. Lactation: Drug is excreted in milk in low concentrations; use not recommended (American Academy of Pediatrics committee states that drug is compatible with nursing)

Pregnancy-Lactation

Interactions

Concurrent use w/ oral anticoagulants may increase prothrombin time.

Adverse Effects

Side effects of Aztreonam : >10% Injection Pain at injection site (12%; children); (2%; adults) Increase in serum transaminases (4-6%) Neutropenia (3-11%, children); (<1%, adults) 1-10% Rash (4%),Thrombocytopenia (4%, children); (<1% adults),Diarrhea (1%),Nausea (1%),Vomiting (1%),Fever (<1%) < 1% Abnormal taste,Anaphylaxis,Anemia,Angioedema,Aphthous ulcer,Breast tenderness,Bronchospasm,Clostridium difficile-associated diarrhea (CDAD),Confusion,Diplopia,Dizziness,Dsypnea,Electrocardiographic changes (transient),Erythema multiforme,Eosinophilia,Fever,Flushing,Halitosis,Headache,Hepatitis,Hypotension,Insomnia,Jaundice,Leukocytosis,Neutropenia,Pancytopenia,Seizures,Thrombocytopenia,Tinnitus,Tongue numbness,Toxic epidermal necrolysis,Urticaria,Vaginitis,Vertigo,Weakness,Wheezing Potentially Fatal: Clostridium difficile-associated diarrhoea from mild diarrhoea to fatal colitis.

Mechanism of Action

Aztreonam inhibits bacterial cell wall synthesis due to its high affinity for penicillin-binding protein 3 (PBP-3) of gm-ve bacteria. It is highly resistant to hydrolysis by many narrow-spectrum β-lactamases. It is also active against most Enterobacteriaceae (including E. coli, Citrobacter, Enterobacter, Klebsiella, Proteus, Providencia, Salmonella, Serratia, Shigella, Yersinia spp. and Morganella morganii).

Note

Azenam 250 250mg Injection manufactured by Aristo Pharmaceuticals Ltd.. Its generic name is Aztreonam. Azenam 250 is availble in Nepal. Farmaco Nepal drug index information on Azenam 250 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Aztreonam :